Biohaven closes $200M public offering at $7.50 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at Morgan Stanley
November 17, 2025 7:38 AM ESTMorgan Stanley analyst Terence Flynn lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $26.00 (from $54.00) while maintaining a Overweight rating.
The analyst comments "BHVN announced on 10/4 that it received a Complete Response Letter (CRL) from the FDA regarding its NDA for... More
